Commonwealth Equity Services, LLC Galecto, Inc. Transaction History

Commonwealth Equity Services, LLC

  • $66 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024
SELL
$0.47 - $0.76 $3,041 - $4,918
-6,472 Reduced 28.77%
16,027 $8,000
Q1 2024

Apr 29, 2024
BUY
$0.6 - $0.89 $3,260 - $4,836
5,434 Added 31.84%
22,499 $18,000
Q4 2023

Feb 06, 2024
SELL
$0.52 - $0.78 $555 - $833
-1,069 Reduced 5.9%
17,065 $12,000
Q3 2023

Oct 23, 2023
BUY
$0.56 - $3.17 $3,464 - $19,609
6,186 Added 51.77%
18,134 $13,000
Q2 2023

Aug 10, 2023
BUY
$1.68 - $2.84 $2,971 - $5,023
1,769 Added 17.38%
11,948 $30,000
Q3 2022

Nov 14, 2022
BUY
$1.59 - $60.0 $16,184 - $610,740
10,179 New
10,179 $19,000

Others Institutions Holding GLTO

# of Institutions
1
Shares Held
21.2K
Call Options Held
0
Put Options Held
0
View Full List

About Galecto, Inc.

GLTO Quotes by TradingView
  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $119M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email